Product category:
Proteomics
News Release from: Proteome Systems
Edited by the Laboratorytalk Editorial
Team on 30 May 2003
Research collaboration in osteoarthritis
Proteome Systems and Iberica announce research collaboration on identifying biomarkers for the treatment of osteoarthritis
Proteome Systems and Iberica have announced an agreement to collaborate on a proteomics and glycomics research programme to analyse the proteoglycan changes associated with the progression and treatment of osteoarthritis Proteoglycans are a major component of the cartilage in joints and contribute towards the lubrication of the articulating surface in the knee
This article was originally published on Laboratorytalk on 21 Dec 2001 at 8.00am (UK)
Related stories
In-gel digest kits for protein sample preparation
Proteome Systems and Millipore announce the new Millipore Montage in-gel digest kits, the first kits introduced since the relationship between the firms was announced earlier this year
Next generation proteomics platform
Combination of separation technology, robotics, mass spectrometr,y and enterprise level computing delivers "comprehensive outcomes" through its ability to decipher proteomic complexity
Nicolle Packer, executive VP glycoproteomics, Proteome Systems, said "The chronic inflammatory process seen in osteoarthritis results in the loss of cartilage matrix in over 80% of middle-aged individuals, causing severe musculoskeletal pain and disability.
The socio-economic consequences of osteoarthritis are considerable and are escalating as people live longer.
We have the technology to be able to measure the effects of this process and to find markers which will enable us to detect and monitor disease progression/regression and response to treatment, earlier than is possible in the clinic today." "This programme is part of an Iberica-Kurume Translational Research Center collaboration with Professor Kensei Nagata, chief director of the Department of Orthopaedics, Kurume University, to find a biomarker which may be used for diagnosis and/or treatment of osteoarthritis" said Misayo Abe, CEO, Iberica.
"There is currently no available, accurate biochemical measure of the course, or treatment, of this widespread disease.
Proteome Systems will conduct the proteomic research in its Sydney laboratories on patient samples provided by Iberica-Kurume.".
• Proteome Systems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
